Literature DB >> 12584340

Tat-neutralizing antibodies in vaccinated macaques.

Ilia Tikhonov1, Tracy J Ruckwardt, Glen S Hatfield, C David Pauza.   

Abstract

The human immunodeficiency virus Tat protein is essential for virus replication and is a candidate vaccine antigen. Macaques immunized with Tat or chemically modified Tat toxoid having the same clade B sequence developed strong antibody responses. We compared these antisera for their abilities to recognize diverse Tat sequences. An overlapping peptide array covering three clade B and two clade C Tat sequences was constructed to help identify reactive linear epitopes. Sera from Tat-immunized macaques were broadly cross-reactive with clade B and clade C sequences but recognized a clade B-specific epitope in the basic domain. Sera from Tat toxoid-immunized macaques had a more restricted pattern of recognition, reacting mainly with clade B and with only one clade B basic domain sequence, which included the rare amino acids RPPQ at positions 57 to 60. Monoclonal antibodies against the amino terminus or the domain RPPQ sequence blocked Tat uptake into T cells and neutralized Tat in a cell-based transactivation assay. Macaques immunized with Tat or Tat toxoid proteins varied in their responses to minor epitopes, but all developed a strong response to the amino terminus, and antisera were capable of neutralizing Tat in a transactivation assay.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12584340      PMCID: PMC149747          DOI: 10.1128/jvi.77.5.3157-3166.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge.

Authors:  S S Cohen; C Li; L Ding; Y Cao; A B Pardee; E M Shevach; D I Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

2.  Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine.

Authors:  R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

Review 3.  Multifaceted activities of the HIV-1 transactivator of transcription, Tat.

Authors:  K T Jeang; H Xiao; E A Rich
Journal:  J Biol Chem       Date:  1999-10-08       Impact factor: 5.157

4.  HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes.

Authors:  J M Weiss; A Nath; E O Major; J W Berman
Journal:  J Immunol       Date:  1999-09-01       Impact factor: 5.422

5.  Cutting edge: a short polypeptide domain of HIV-1-Tat protein mediates pathogenesis.

Authors:  R A Boykins; R Mahieux; U T Shankavaram; Y S Gho; S F Lee; I K Hewlett; L M Wahl; H K Kleinman; J N Brady; K M Yamada; S Dhawan
Journal:  J Immunol       Date:  1999-07-01       Impact factor: 5.422

6.  Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients.

Authors:  M C Re; M Vignoli; G Furlini; D Gibellini; V Colangeli; F Vitone; M La Placa
Journal:  J Clin Virol       Date:  2001-04       Impact factor: 3.168

7.  Circulating natural IgM antibodies and their corresponding human cord blood cell-derived Mabs specifically combat the Tat protein of HIV.

Authors:  T C Rodman; J D Lutton; S Jiang; H B Al-Kouatly; R Winston
Journal:  Exp Hematol       Date:  2001-08       Impact factor: 3.084

8.  In vivo protein transduction: delivery of a biologically active protein into the mouse.

Authors:  S R Schwarze; A Ho; A Vocero-Akbani; S F Dowdy
Journal:  Science       Date:  1999-09-03       Impact factor: 47.728

9.  Identification of a potential HIV-induced source of bystander-mediated apoptosis in T cells: upregulation of trail in primary human macrophages by HIV-1 tat.

Authors:  M Zhang; X Li; X Pang; L Ding; O Wood; K Clouse; I Hewlett; A I Dayton
Journal:  J Biomed Sci       Date:  2001 May-Jun       Impact factor: 8.410

10.  Homonuclear (1)H-NMR assignment and structural characterization of human immunodeficiency virus type 1 Tat Mal protein.

Authors:  C Grégoire; J M Péloponèse; D Esquieu; S Opi; G Campbell; M Solomiac; E Lebrun; J Lebreton; E P Loret
Journal:  Biopolymers       Date:  2001       Impact factor: 2.505

View more
  15 in total

1.  Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen.

Authors:  Emmanuel Moreau; Johan Hoebeke; Daniel Zagury; Sylviane Muller; Claude Desgranges
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

2.  Effect of the redox state on HIV-1 tat protein multimerization and cell internalization and trafficking.

Authors:  Raffaella Pierleoni; Michele Menotta; Antonella Antonelli; Carla Sfara; Giordano Serafini; Sabrina Dominici; Maria Elena Laguardia; Annalisa Salis; Gianluca Damonte; Lucia Banci; Marco Porcu; Paolo Monini; Barbara Ensoli; Mauro Magnani
Journal:  Mol Cell Biochem       Date:  2010-08-20       Impact factor: 3.396

3.  Extracellular HIV Tat and Tat cysteine rich peptide increase CCR5 expression in monocytes.

Authors:  Lin Zheng; Yi-da Yang; Guo-cai Lu; Maria S Salvato
Journal:  J Zhejiang Univ Sci B       Date:  2005-07       Impact factor: 3.066

4.  Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.

Authors:  Laurent Mascarell; Catherine Fayolle; Cécile Bauche; Daniel Ladant; Claude Leclerc
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Novel biopanning strategy to identify epitopes associated with vaccine protection.

Authors:  Barbara C Bachler; Michael Humbert; Brisa Palikuqi; Nagadenahalli B Siddappa; Samir K Lakhashe; Robert A Rasmussen; Ruth M Ruprecht
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

6.  Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism.

Authors:  Yida Yang; Ilia Tikhonov; Tracy J Ruckwardt; Mahmoud Djavani; Juan Carlos Zapata; C David Pauza; Maria S Salvato
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

7.  HIV immune complexes prevent excitotoxicity by interaction with NMDA receptors.

Authors:  Jeffrey A Rumbaugh; Muznabanu Bachani; Wenxue Li; Tracy R Butler; Katherine J Smith; Mario A Bianchet; Tongguang Wang; Mark A Prendergast; Ned Sacktor; Avindra Nath
Journal:  Neurobiol Dis       Date:  2012-08-25       Impact factor: 5.996

8.  Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein.

Authors:  Tracy J Ruckwardt; Ilia Tikhonov; Shannon Berg; Glen S Hatfield; Angelika Chandra; Prakash Chandra; Bruce Gilliam; Robert R Redfield; Robert C Gallo; C David Pauza
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 9.  Polyphosphazene immunoadjuvants: Historical perspective and recent advances.

Authors:  Alexander K Andrianov; Robert Langer
Journal:  J Control Release       Date:  2020-12-05       Impact factor: 9.776

Review 10.  HIV-1 gp120 binding to dendritic cell receptors mobilize the virus to the lymph nodes, but the induced IL-4 synthesis by FcepsilonRI+ hematopoietic cells damages the adaptive immunity--a review, hypothesis, and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2004-08       Impact factor: 2.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.